{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:39:56Z","timestamp":1775831996637,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Spanish Health Ministry \u201cFondo de Investigaci\u00f3n Sanitaria\u201d","award":["EC 10-136"],"award-info":[{"award-number":["EC 10-136"]}]},{"name":"Spanish Health Ministry \u201cFondo de Investigaci\u00f3n Sanitaria\u201d","award":["PI10\/01807"],"award-info":[{"award-number":["PI10\/01807"]}]},{"name":"AECC Catalu\u00f1a 2011, Instituto de Salud Carlos III FEDER","award":["RD09\/0076\/00036"],"award-info":[{"award-number":["RD09\/0076\/00036"]}]},{"name":"AECC Catalu\u00f1a 2011, Instituto de Salud Carlos III FEDER","award":["RD12\/0036\/0010"],"award-info":[{"award-number":["RD12\/0036\/0010"]}]},{"name":"\u201cXarxa de Bancs de Tumors sponsored by Pla Director d\u2019Oncologia de Catalunya (XBTC)\u201d"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.leukres.2013.03.013","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T11:04:28Z","timestamp":1366196668000},"page":"917-921","source":"Crossref","is-referenced-by-count":28,"title":["Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide"],"prefix":"10.1016","volume":"37","author":[{"given":"Anna","family":"Angona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Alvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz","family":"Mart\u00ednez-Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Pairet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Concepci\u00f3n","family":"Fern\u00e1ndez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c0gueda","family":"Ancochea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carles","family":"Besses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.03.013_bib0005","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.leukres.2013.03.013_bib0010","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2013.03.013_bib0015","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2013.03.013_bib0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2013.03.013_bib0025","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.03.013_bib0030","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1365-2141.2009.07804.x","article-title":"Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients","volume":"146","author":"Alvarez-Larr\u00e1n","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.03.013_bib0035","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.leukres.2013.03.013_bib0040","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.leukres.2013.03.013_bib0045","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.leukres.2013.03.013_bib0050","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.leukres.2011.09.029","article-title":"Influence of JAK2 46\/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms","volume":"36","author":"Alvarez-Larran","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.03.013_bib0055","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from european LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.03.013_bib0060","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2141.2010.08467.x","article-title":"Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients","volume":"152","author":"Besses","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.03.013_bib0065","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.exphem.2011.01.004","article-title":"Transcellular movement of hydroxyurea is mediated by specific solute carrier transporters","volume":"39","author":"Walker","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.leukres.2013.03.013_bib0070","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2011-07-364190","article-title":"Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia","volume":"118","author":"Ware","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.03.013_bib0075","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.03.013_bib0080","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.03.013_bib0085","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a european LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261300088X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261300088X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T03:48:52Z","timestamp":1688183332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261300088X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S014521261300088X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.03.013","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}